PMV Pharmaceuticals, Inc. (PMVP) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Schroeder Thilo

Director

—

$38.34M (97)

−$38.34M

2,687,236

5.03%

$4.08M

+106.5%

Boxer Capital, LLC entity

Former 10% Owner

$17.10M (1)

—

+$17.10M

2,329,073

4.36%

$3.54M

—

RA CAPITAL MANAGEMENT, L.P. entity

10% owner

$17.10M (1)

—

+$17.10M

1,710,265

3.20%

$2.60M

—

Thompson Peter A.

Director

$17.10M (2)

—

+$17.10M

114,039

0.2133%

$173.34K

—

Euclidean Capital LLC entity

10% owner

—

$6.36M (30)

−$6.36M

259,700

0.4858%

$394.74K

—

ORBIMED ADVISORS LLC entity

10% owner

$17.10M (2)

$13.30M (7)

+$3.80M

5,089,330

9.52%

$7.74M

+4,382%

Mack David Henry

President and CEO

—

$1.56M (6) scheduled

−$1.56M

673,394

1.26%

$1.02M

—

INTERWEST PARTNERS X LP entity

10% owner

$990.00K (1)

—

+$990.00K

4,502,480

8.42%

$6.84M

+811,158%

ORONSKY ARNOLD L

Director

$990.00K (1)

—

+$990.00K

6,469,356

12.10%

$9.83M

—

Alland Leila

Chief Medical Officer

—

$853.20K (14) scheduled

−$853.20K

45,909

0.0859%

$69.78K

+9,647%

Kung Winston

COO, CFO

—

$607.80K (4) scheduled

−$607.80K

10,600

0.0198%

$16.11K

+100.6%

LEVINE ARNOLD J

Director

—

$568.31K (7)

−$568.31K

409,842

0.7667%

$622.96K

−4.1%

Jalota Deepika

Chief Development Officer

—

$171.03K (4) scheduled

−$171.03K

89,959

0.1683%

$136.74K

+1,797%

Heyman Richard A.

Director

—

$126.94K (9) scheduled

−$126.94K

0

0.0000%

$0.00

—

Carulli Michael

Chief Financial Officer

—

$34.42K (2)

−$34.42K

60,146

0.1125%

$91.42K

+563.4%

Ticktin Robert

General Counsel & COO

—

$24.65K (1)

−$24.65K

98,695

0.1846%

$150.02K

−19.0%

Nextech V Oncology S.C.S., SICAV-SIF

Former 10% Owner

—

2,528,290

4.73%

$3.84M

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

Former 10% Owner

—

760,267

1.42%

$1.16M

—

PMV Pharmaceuticals, Inc.

By person

Individual transactions

What was left out